Vismodegib and Atezolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, vismodegib and atezolizumab, for people with non-small cell lung cancer that has spread or come back after standard treatments. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your non-small cell lung cancer has spread to other parts of the body or come back after treatment, and there are no standard cures left.
- You have measurable tumors (can be seen on scans).
- You have already received standard chemotherapy and/or immunotherapy (no limit on how many prior treatments).
- If you have adenocarcinoma with known gene mutations (like EGFR or ALK), you must have tried all approved targeted therapies for those mutations.
- You must be willing to have a biopsy and provide tumor tissue samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
This trial tests a new treatment for advanced non-small cell lung cancer that has certain gene changes (like ALK, EGFR, or ROS1) and has already been treated with targeted therapy and chemotherapy. It aims to find out if the study drug can help when previous treatments stop working.
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Hear when a new Metastatic Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.